Stocktoria
Aquestive Therapeutics, Inc. AQST
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2018-07-25
Aquestive Therapeutics, Inc. statistics & valuation
Market cap$550.7M
P / S12.4×
Net margin-188.1%
FCF margin-119.0%
Net cash$76.2M
Enterprise value USD$474.6M
Earnings yield EBIT/EV-15%
Return on capital-63%
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating margin | -159.5% | -53.5% | -29.9% | -88.2% | -68.2% | -93.6% | -100.1% | -72.6% | -0.2% |
| Net margin | -188.1% | -76.7% | -15.6% | -114.1% | -138.8% | -121.7% | -125.9% | -91.0% | -13.4% |
| FCF margin | -119.0% | -62.4% | -14.6% | -22.7% | -66.7% | -100.3% | -115.7% | -22.0% | 5.6% |
| Return on assets | -52.2% | -43.5% | -13.7% | -95.3% | -113.8% | -88.7% | -84.4% | -70.7% | -20.7% |
| Return on equity | 248.9% | 73.4% | 7.4% | 45.9% | 85.9% | 115.0% | 1082.1% | -608.9% | 33.8% |
| Debt / equity | -1.34× | -0.75× | -0.42× | — | — | -1.06× | -11.43× | — | — |
| Current ratio | 3.14 | 4.68 | 2.24 | 1.01 | 2.15 | 2.11 | 3.68 | 2.25 | 1.83 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.